Oppenheimer raised the firm’s price target on Artivion (AORT) to $50 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 revenue of $113.4M, +16% year-over-year, above its/consensus estimate of $112M/$110M. FY25 revenue guidance was raised, now $439M-$445M, and management remains confident about double-digit top-line growth.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion price target raised to $40 from $38 at Ladenburg
- Artivion price target raised to $51 from $50 at Canaccord
- Artivion price target raised to $53 from $47 at Citizens JMP
- Artivion’s Strong Q3 Performance and Growth Prospects Justify Buy Rating
- Artivion Inc. Reports Strong Q3 2025 Financial Results